Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods.
Alzheimer’s disease
Amyloid beta
Biomarkers
Cerebrospinal fluid
Collection
Concordance
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
16 04 2021
16 04 2021
Historique:
received:
08
02
2021
accepted:
22
03
2021
entrez:
17
4
2021
pubmed:
18
4
2021
medline:
25
6
2021
Statut:
epublish
Résumé
CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profiles in CSF extracted using either gravity drip or aspiration. Biomarkers for β-amyloidopathy (Aβ1-42, Aβ1-40), tauopathy (total tau), or synapse pathology (BACE1, Neurogranin Trunc-p75, α-synuclein) were assessed between gravity or aspiration extraction methods in a sub-population of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (cognitively normal, N = 36; mild cognitive impairment, N = 8; Alzheimer's disease, N = 6). High biomarker concordance between extraction methods was seen (concordance correlation > 0.85). Passing Bablock regression defined low beta coefficients indicating high scalability. Levels of these commonly assessed CSF biomarkers are not influenced by extraction method. Results of this study should be incorporated into new consensus guidelines for CSF collection, storage, and analysis of biomarkers.
Sections du résumé
BACKGROUND
CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profiles in CSF extracted using either gravity drip or aspiration.
METHODS
Biomarkers for β-amyloidopathy (Aβ1-42, Aβ1-40), tauopathy (total tau), or synapse pathology (BACE1, Neurogranin Trunc-p75, α-synuclein) were assessed between gravity or aspiration extraction methods in a sub-population of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (cognitively normal, N = 36; mild cognitive impairment, N = 8; Alzheimer's disease, N = 6).
RESULTS
High biomarker concordance between extraction methods was seen (concordance correlation > 0.85). Passing Bablock regression defined low beta coefficients indicating high scalability.
CONCLUSIONS
Levels of these commonly assessed CSF biomarkers are not influenced by extraction method. Results of this study should be incorporated into new consensus guidelines for CSF collection, storage, and analysis of biomarkers.
Identifiants
pubmed: 33863377
doi: 10.1186/s13195-021-00812-9
pii: 10.1186/s13195-021-00812-9
pmc: PMC8052760
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Peptide Fragments
0
tau Proteins
0
Amyloid Precursor Protein Secretases
EC 3.4.-
Aspartic Acid Endopeptidases
EC 3.4.23.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
79Références
Mov Disord. 2017 Aug;32(8):1117-1130
pubmed: 28734051
Arch Neurol. 2011 Sep;68(9):1137-44
pubmed: 21555603
Acta Neuropathol. 2018 Dec;136(6):821-853
pubmed: 30488277
Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4
pubmed: 25443857
Alzheimers Dement. 2021 Mar 31;:
pubmed: 33788410
Ann Neurol. 2010 Sep;68(3):319-29
pubmed: 20687209
Neurology. 2018 Oct 2;91(14):e1295-e1306
pubmed: 30217935
Molecules. 2020 Feb 21;25(4):
pubmed: 32098280
Alzheimers Dement. 2016 Feb;12(2):154-163
pubmed: 26368321
J Alzheimers Dis. 2016 May 31;53(3):1121-32
pubmed: 27258423
J Appl Lab Med. 2021 Mar 1;6(2):397-408
pubmed: 33249440
Alzheimers Res Ther. 2015 Nov 19;7(1):71
pubmed: 26581886
Neuroimage. 2018 Dec;183:387-393
pubmed: 30130643
Lancet Neurol. 2010 Jan;9(1):119-28
pubmed: 20083042
Alzheimers Dement. 2018 Oct;14(10):1313-1333
pubmed: 29940161
Int Psychogeriatr. 2009 Aug;21(4):672-87
pubmed: 19470201
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Lancet Neurol. 2003 Oct;2(10):605-13
pubmed: 14505582
Prog Mol Biol Transl Sci. 2019;168:3-23
pubmed: 31699324
Neurobiol Aging. 2010 Aug;31(8):1275-83
pubmed: 20472326
J Nucl Med. 2010 Jun;51(6):913-20
pubmed: 20501908
Nat Rev Neurol. 2010 Mar;6(3):131-44
pubmed: 20157306
Alzheimers Dement. 2018 Nov;14(11):1505-1521
pubmed: 30316776
Alzheimers Dement. 2013 May;9(3):251-61
pubmed: 23622690
Alzheimers Dement. 2020 Nov;16(11):1493-1503
pubmed: 32755010
Biomark Med. 2012 Aug;6(4):419-30
pubmed: 22917144
Brain. 2016 Apr;139(Pt 4):1226-36
pubmed: 26936941
Alzheimers Dement. 2012 Jan;8(1):65-73
pubmed: 22047631
Neurol Ther. 2019 Dec;8(Suppl 2):129-145
pubmed: 31833029
Clin Chem. 2015 May;61(5):734-43
pubmed: 25869575
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248